Inoperable small cell and non-small cell lung cancer.
Conditions
Interventions
Hypofractionated Treatment Group:Hypofractionated Treatment
Sponsors
The Second Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Able to provide written informed consent and understand and agree to follow the study requirements and assessment schedule. 2.Ages: 18 to 75 years old; 3.Patients with small cell and non-small cell lung cancer diagnosed as inoperable by pathological examination. 4.ECOG score: 0 - 2 points. 5.Expected survival period >= 3 months. 6.Patients should have measurable or evaluable target lesions. 7.Normal major organ function, meeting the following criteria:(1) The blood routine examination standards need to meet (no blood transfusion and blood products within 14 days, and no use of G-CSF and other hematopoietic stimulating factors for correction): a. HB>=100 g/L; b. ANC>=1.5×10^9/L; c. PLT>=100×10^9/L; (2) Biochemical examinations need to meet the following standards: a. TBIL 50 ml/min (Cockcroft-Gault formula); (3) Pulmonary function: FEV>=1L or >50% of the predicted value. 8.Women of childbearing age must ensure contraception during the study period. 9.Women of childbearing age must ensure contraception during the study period.
Exclusion criteria
Exclusion criteria: 1.Patients with pathological types and primary lesion sites that do not meet the inclusion criteria. 2.Patients who are not suitable to receive the radiotherapy regimen specified in the protocol. 3.Having any active malignant tumors within =5% within 1 month before treatment or other indicators showing severe malnutrition; 8.Pregnant or lactating women and women who refuse contraception during the treatment and observation period. 9.Individuals with personality or mental disorders, or those without or with limited civil conduct capacity. 10.Patients have participated in other anticancer drug clinical trials within 4 weeks; 11.Refuse or are unable to sign the informed consent form. 12.The investigator deems that there are other circumstances that may affect the conduct of the clinical study and the assessment of the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year and 5-year survival rates.;Tumor Marker;Disease Control Rate;Quality of Life Score;Progression Free Survival;Adverse Reactions; | — |
Countries
China
Contacts
Public ContactXixi Zhao
The Second Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed